A cross sectional study on assessment of risk factors and utilization of GDMT on dilated cardiomyopathy patients having follow up at cardiac clinic, TASH presented to internal medicine department, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia from Sep, 2019 - Aug, 2020.
| dc.contributor.advisor | A, Mebratu (MD, Assistant Professor of cardiology TASH, Department of internal medicine) | |
| dc.contributor.author | Mulugeta, Marshet | |
| dc.date.accessioned | 2021-02-08T11:06:31Z | |
| dc.date.accessioned | 2023-11-05T09:37:02Z | |
| dc.date.available | 2021-02-08T11:06:31Z | |
| dc.date.available | 2023-11-05T09:37:02Z | |
| dc.date.issued | 2020-12 | |
| dc.description.abstract | Background: Dilated Cardiomyopathy which is the commonest of the cardiomyopathies is an important cause of cardiac-related morbidity and mortality globally. Despite the significant health impact associated with this disease, reliable data regarding the assessment of risk factors and therapy of these patients is lacking. Objective: This study aimed to identify the possible risk factors associated with dilated cardiomyopathy and assess the optimization of GDMT in this patient population. Methods: Hospital based crossectional study was conducted at TASH. The study included 107 patients who had follow up at TASH from Sep 2019 – Aug 2020. A semi structured selfadministered questionnaire and data from EMR was collected and used for analysis. The results were interpreted using descriptive statistics. Results: Of the total of 107 patients 12.1% patients reported family history of cardiac illness, 30.8 % had a significant alcohol and/or chat intake, 16% had peripartal diagnosis, 6.5 % were HIV infected patients, 1.8 % had history of thyrotoxicosis and 6.5% had antracycline chemotherapy treatment. Regarding therapy; 89.7% of our patients were on beta blocker while 91.4 % of patients were on ACEI/ARB/ARNI and 58.9 were taking MRA. The majority of patients were on suboptimal doses of all groups of medication. Conclusion: In the majority of our patients risk factors underlying the disease could be identified upon detailed inquiry. While most of our patients are on appropriate GDMT, the dose of the medications taken was far lower than that of the target dose as stated by the guidelines. | en_US |
| dc.identifier.uri | http://etd.aau.edu.et/handle/123456789/25024 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Addis Abeba University | en_US |
| dc.subject | GDMT, cardiomyopathy patients , cardiac clinic | en_US |
| dc.title | A cross sectional study on assessment of risk factors and utilization of GDMT on dilated cardiomyopathy patients having follow up at cardiac clinic, TASH presented to internal medicine department, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Ethiopia from Sep, 2019 - Aug, 2020. | en_US |
| dc.type | Thesis | en_US |